Table 2.
MBL2 genotypes and protein concentration in hepatitis C virus (HCV) patients and controls.
| MBL2 genotype | HCV patients | Controls | ||||||
|---|---|---|---|---|---|---|---|---|
| n1 = 102 | % | n2 = 82 | (MBL ng/ml) | n1 = 102 | % | n2 = 50 | (MBL ng/ml) | |
| YA/YA | 30 | 29·4 | 23 | 2413 (481–5594) | 39 | 38·2 | 20 | 2093·5 (280–5023) |
| XA/YA | 23 | 22·5 | 20 | 1579 (479–4059) | 20 | 19·6 | 11 | 915 (513–2600) |
| YA/YO | 32 | 31·4 | 26 | 370·5 (107–2713) | 17 | 16·7 | 12 | 520 (97–3100) |
| XA/XA | 6 | 5·9 | 6 | 423 (36–1388) | 6 | 5·9 | 2 | 279 (195–363) |
| XA/YO | 9 | 8·8 | 6 | 71·5 (11–835) | 12 | 11·8 | 1 | 47 |
| YO/YO | 2 | 2 | 1 | < 10 | 8 | 7·8 | 4 | < 10 |
The medians of mannose-binding lactose (MBL) levels on admission are given, followed by the range of values in parentheses. Bold type, significant difference (P = 0·022, odds ratio 2·29, confidence interval 95% 1·17–4·46). n1, number of genotyped individuals, n2, number of serologically quantified individuals.